Skip to main content
Erschienen in: Obesity Surgery 1/2012

01.01.2012 | Clinical Research

Prevalence of Endocrine Disorders in Morbidly Obese Patients and the Effects of Bariatric Surgery on Endocrine and Metabolic Parameters

verfasst von: Draženka Janković, Peter Wolf, Christian-Heinz Anderwald, Yvonne Winhofer, Miriam Promintzer-Schifferl, Astrid Hofer, Felix Langer, Gerhard Prager, Bernhard Ludvik, Alois Gessl, Anton Luger, Michael Krebs

Erschienen in: Obesity Surgery | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Several endocrine abnormalities, including hypothyroidism and Cushing’s syndrome (CS), are considered as causative factors of obesity. The aim of this study was to evaluate the prevalence of endocrine disorders and obesity-associated co-morbidities, as well as the impact of substantial weight loss.

Methods

Screening was performed in 433 consecutive morbidly obese patients (age 41 ± 12 years; BMI 47 ± 6.9 kg/m2; women 76%). A 1-mg dexamethasone suppression test (1-mg DST) was conducted to exclude CS, and thyrotropin (TSH) was measured to exclude hypothyroidism. Insulin sensitivity was estimated from oral glucose tolerance tests employing the Clamp-like index. Examinations were carried out at baseline, as well as at 6 and 12 months postoperatively.

Results

The prevalence of CS was below 0.6%. Before surgery, TSH was elevated compared to an age- and sex-matched normal weight control group (2.4 ± 1.2 vs. 1.5 ± 0.7 μU/ml; p < 0.001). The NCEP criteria of metabolic syndrome (MetS) were fulfilled by 39.5% of the patients. Impaired glucose tolerance and diabetes mellitus were observed in 23.5% and 22.6%, respectively. Seventy-two percent were insulin resistant. During follow-up, weight (BMI 47 ± 6.9 vs. 36 ± 6.4 vs. 32 ± 6.6 kg/m2; p < 0.001) and TSH decreased significantly (2.4 ± 1.2 vs. 1.8 ± 1.0 vs. 1.8 ± 1.0 μU/ml; p < 0.001). Serum cortisol was higher in the MetS+-group compared to the MetS--group (15.0 ± 6.3 vs. 13.5 ± 6.3 μg/dl; p = 0.003).

Conclusions

CS appears to be a rare cause of morbid obesity. Normalization of slightly elevated thyrotropin after weight loss suggests that obesity causes TSH elevation rather than the reverse.
Literatur
1.
Zurück zum Zitat Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metab Clin North Am. 2003;32:895–914.PubMedCrossRef Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metab Clin North Am. 2003;32:895–914.PubMedCrossRef
2.
Zurück zum Zitat Maddox GL, Liederman V. Overweight as a social disability with medical implications. J Med Educ. 1969;44:214–20.PubMed Maddox GL, Liederman V. Overweight as a social disability with medical implications. J Med Educ. 1969;44:214–20.PubMed
3.
Zurück zum Zitat Price JH, Desmond SM, Krol RA, et al. Family practice physicians’ beliefs, attitudes, and practices regarding obesity. Am J Prev Med. 1987;3:339–45.PubMed Price JH, Desmond SM, Krol RA, et al. Family practice physicians’ beliefs, attitudes, and practices regarding obesity. Am J Prev Med. 1987;3:339–45.PubMed
4.
Zurück zum Zitat Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid function in humans with morbid obesity. Thyroid. 2006;16:73–8.PubMedCrossRef Michalaki MA, Vagenakis AG, Leonardou AS, et al. Thyroid function in humans with morbid obesity. Thyroid. 2006;16:73–8.PubMedCrossRef
5.
Zurück zum Zitat Sari R, Balci MK, Altunbas H, et al. The effect of body weight and weight loss on thyroid volume and function in obese women. Clin Endocrinol (Oxf). 2003;59:258–62.CrossRef Sari R, Balci MK, Altunbas H, et al. The effect of body weight and weight loss on thyroid volume and function in obese women. Clin Endocrinol (Oxf). 2003;59:258–62.CrossRef
6.
Zurück zum Zitat Raftopoulos Y, Gagne DJ, Papasavas P, et al. Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004;14:509–13.PubMedCrossRef Raftopoulos Y, Gagne DJ, Papasavas P, et al. Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004;14:509–13.PubMedCrossRef
7.
Zurück zum Zitat Fazylov R, Soto E, Cohen S, et al. Laparoscopic Roux-en-Y gastric bypass surgery on morbidly obese patients with hypothyroidism. Obes Surg. 2008;18:644–7.PubMedCrossRef Fazylov R, Soto E, Cohen S, et al. Laparoscopic Roux-en-Y gastric bypass surgery on morbidly obese patients with hypothyroidism. Obes Surg. 2008;18:644–7.PubMedCrossRef
8.
Zurück zum Zitat Alagna S, Cossu ML, Masala A, et al. Evaluation of serum leptin levels and thyroid function in morbidly obese patients treated with bariatric surgery. Eat Weight Disord. 2003;8:95–9.PubMed Alagna S, Cossu ML, Masala A, et al. Evaluation of serum leptin levels and thyroid function in morbidly obese patients treated with bariatric surgery. Eat Weight Disord. 2003;8:95–9.PubMed
9.
Zurück zum Zitat Buscemi S, Verga S, Maneri R, et al. Influences of obesity and weight loss on thyroid hormones. A 3–3.5-year follow-up study on obese subjects with surgical bilio-pancreatic by-pass. J Endocrinol Invest. 1997;20:276–81.PubMed Buscemi S, Verga S, Maneri R, et al. Influences of obesity and weight loss on thyroid hormones. A 3–3.5-year follow-up study on obese subjects with surgical bilio-pancreatic by-pass. J Endocrinol Invest. 1997;20:276–81.PubMed
10.
Zurück zum Zitat Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88:5808–13.PubMedCrossRef Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88:5808–13.PubMedCrossRef
11.
Zurück zum Zitat Omura M, Saito J, Yamaguchi K, et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27:193–202.PubMedCrossRef Omura M, Saito J, Yamaguchi K, et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27:193–202.PubMedCrossRef
12.
Zurück zum Zitat Anderson Jr GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609–15.PubMedCrossRef Anderson Jr GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609–15.PubMedCrossRef
13.
Zurück zum Zitat Tiryakioglu O, Ugurlu S, Yalin S, et al. Screening for Cushing’s syndrome in obese patients. Clinics (Sao Paulo). 2010;65:9–13.CrossRef Tiryakioglu O, Ugurlu S, Yalin S, et al. Screening for Cushing’s syndrome in obese patients. Clinics (Sao Paulo). 2010;65:9–13.CrossRef
14.
Zurück zum Zitat Anderwald C, Anderwald-Stadler M, Promintzer M, et al. The Clamp-like index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. Diabetes Care. 2007;30:2374–80.PubMedCrossRef Anderwald C, Anderwald-Stadler M, Promintzer M, et al. The Clamp-like index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. Diabetes Care. 2007;30:2374–80.PubMedCrossRef
15.
Zurück zum Zitat Promintzer M, Krebs M, Todoric J, et al. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab. 2007;92:4306–12.PubMedCrossRef Promintzer M, Krebs M, Todoric J, et al. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab. 2007;92:4306–12.PubMedCrossRef
16.
Zurück zum Zitat Chiodini I. Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011. Chiodini I. Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011.
17.
Zurück zum Zitat Nickelsen T, Lissner W, Schoffling K. The dexamethasone suppression test and long-term contraceptive treatment: measurement of ACTH or salivary cortisol does not improve the reliability of the test. Exp Clin Endocrinol. 1989;94:275–80.PubMedCrossRef Nickelsen T, Lissner W, Schoffling K. The dexamethasone suppression test and long-term contraceptive treatment: measurement of ACTH or salivary cortisol does not improve the reliability of the test. Exp Clin Endocrinol. 1989;94:275–80.PubMedCrossRef
18.
Zurück zum Zitat Qureshi AC, Bahri A, Breen LA, et al. The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf). 2007;66:632–5.CrossRef Qureshi AC, Bahri A, Breen LA, et al. The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf). 2007;66:632–5.CrossRef
19.
Zurück zum Zitat Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526–40.PubMedCrossRef Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526–40.PubMedCrossRef
20.
Zurück zum Zitat Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
21.
Zurück zum Zitat Baid SK, Rubino D, Sinaii N, et al. Specificity of screening tests for Cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab. 2009;94:3857–64.PubMedCrossRef Baid SK, Rubino D, Sinaii N, et al. Specificity of screening tests for Cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab. 2009;94:3857–64.PubMedCrossRef
22.
23.
Zurück zum Zitat Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am. 2002;31:173–89.PubMedCrossRef Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am. 2002;31:173–89.PubMedCrossRef
24.
Zurück zum Zitat al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab. 1997;82:1118–25.PubMedCrossRef al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab. 1997;82:1118–25.PubMedCrossRef
25.
Zurück zum Zitat Sorisky A, Bell A, Gagnon A. TSH receptor in adipose cells. Horm Metab Res. 2000;32:468–74.PubMedCrossRef Sorisky A, Bell A, Gagnon A. TSH receptor in adipose cells. Horm Metab Res. 2000;32:468–74.PubMedCrossRef
26.
Zurück zum Zitat Valyasevi RW, Harteneck DA, Dutton CM, et al. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002;87:2352–8.PubMedCrossRef Valyasevi RW, Harteneck DA, Dutton CM, et al. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002;87:2352–8.PubMedCrossRef
27.
Zurück zum Zitat Guo F, Bakal K, Minokoshi Y, et al. Leptin signaling targets the thyrotropin-releasing hormone gene promoter in vivo. Endocrinology. 2004;145:2221–7.PubMedCrossRef Guo F, Bakal K, Minokoshi Y, et al. Leptin signaling targets the thyrotropin-releasing hormone gene promoter in vivo. Endocrinology. 2004;145:2221–7.PubMedCrossRef
28.
Zurück zum Zitat Kok P, Roelfsema F, Langendonk JG, et al. High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. J Clin Endocrinol Metab. 2005;90:4659–63.PubMedCrossRef Kok P, Roelfsema F, Langendonk JG, et al. High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. J Clin Endocrinol Metab. 2005;90:4659–63.PubMedCrossRef
29.
Zurück zum Zitat de Moraes CM Moulin, Mancini MC, de Melo ME, et al. Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. Obes Surg. 2005;15:1287–91.CrossRef de Moraes CM Moulin, Mancini MC, de Melo ME, et al. Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. Obes Surg. 2005;15:1287–91.CrossRef
31.
Zurück zum Zitat Stewart PM, Boulton A, Kumar S, et al. Cortisol metabolism in human obesity: impaired cortisone– > cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84:1022–7.PubMedCrossRef Stewart PM, Boulton A, Kumar S, et al. Cortisol metabolism in human obesity: impaired cortisone– > cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84:1022–7.PubMedCrossRef
32.
Zurück zum Zitat Hautanen A, Raikkonen K, Adlercreutz H. Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. J Intern Med. 1997;241:451–61.PubMedCrossRef Hautanen A, Raikkonen K, Adlercreutz H. Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. J Intern Med. 1997;241:451–61.PubMedCrossRef
33.
Zurück zum Zitat Manco M, Fernandez-Real JM, Valera-Mora ME, et al. Massive weight loss decreases corticosteroid-binding globulin levels and increases free cortisol in healthy obese patients: an adaptive phenomenon? Diabetes Care. 2007;30:1494–500.PubMedCrossRef Manco M, Fernandez-Real JM, Valera-Mora ME, et al. Massive weight loss decreases corticosteroid-binding globulin levels and increases free cortisol in healthy obese patients: an adaptive phenomenon? Diabetes Care. 2007;30:1494–500.PubMedCrossRef
34.
Zurück zum Zitat Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest. 1997;99:414–23.PubMedCrossRef Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest. 1997;99:414–23.PubMedCrossRef
35.
Zurück zum Zitat Mariniello B, Ronconi V, Rilli S, et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing’s syndrome. Eur J Endocrinol. 2006;155:435–41.PubMedCrossRef Mariniello B, Ronconi V, Rilli S, et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing’s syndrome. Eur J Endocrinol. 2006;155:435–41.PubMedCrossRef
36.
Zurück zum Zitat Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14:794–8.CrossRef Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14:794–8.CrossRef
37.
Zurück zum Zitat Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998;83:1325–35.PubMedCrossRef Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998;83:1325–35.PubMedCrossRef
38.
Zurück zum Zitat Freeman L, Hewison M, Hughes SV, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005;106:2042–9.PubMedCrossRef Freeman L, Hewison M, Hughes SV, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005;106:2042–9.PubMedCrossRef
39.
Zurück zum Zitat Munoz R, Carvajal C, Escalona A, et al. 11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients. Obes Surg. 2009;19:764–70.PubMedCrossRef Munoz R, Carvajal C, Escalona A, et al. 11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients. Obes Surg. 2009;19:764–70.PubMedCrossRef
40.
Zurück zum Zitat Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94:2692–701.PubMedCrossRef Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94:2692–701.PubMedCrossRef
41.
Zurück zum Zitat Ward AM, Fall CH, Stein CE, et al. Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol (Oxf). 2003;58:500–5.CrossRef Ward AM, Fall CH, Stein CE, et al. Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol (Oxf). 2003;58:500–5.CrossRef
42.
Zurück zum Zitat Ravaja N, Keltikangas-Jarvinen L, Viikari J. Life changes, locus of control and metabolic syndrome precursors in adolescents and young adults: a three-year follow-up. Soc Sci Med. 1996;43:51–61.PubMedCrossRef Ravaja N, Keltikangas-Jarvinen L, Viikari J. Life changes, locus of control and metabolic syndrome precursors in adolescents and young adults: a three-year follow-up. Soc Sci Med. 1996;43:51–61.PubMedCrossRef
43.
Zurück zum Zitat Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 2004;30:569–72.PubMedCrossRef Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 2004;30:569–72.PubMedCrossRef
44.
Zurück zum Zitat Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90:4145–50.PubMedCrossRef Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90:4145–50.PubMedCrossRef
45.
Zurück zum Zitat Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond). 2010. Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond). 2010.
46.
Zurück zum Zitat Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643–9.PubMedCrossRef Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643–9.PubMedCrossRef
47.
Zurück zum Zitat Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100:1166–73.PubMedCrossRef Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100:1166–73.PubMedCrossRef
48.
Zurück zum Zitat Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168:1617–24.PubMedCrossRef Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168:1617–24.PubMedCrossRef
Metadaten
Titel
Prevalence of Endocrine Disorders in Morbidly Obese Patients and the Effects of Bariatric Surgery on Endocrine and Metabolic Parameters
verfasst von
Draženka Janković
Peter Wolf
Christian-Heinz Anderwald
Yvonne Winhofer
Miriam Promintzer-Schifferl
Astrid Hofer
Felix Langer
Gerhard Prager
Bernhard Ludvik
Alois Gessl
Anton Luger
Michael Krebs
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Obesity Surgery / Ausgabe 1/2012
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0545-4

Weitere Artikel der Ausgabe 1/2012

Obesity Surgery 1/2012 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.